Autres langues ImmunityBio, Inc.

Actions

IBRX

US45256X1037

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 29/04/2024			Après clotûre 00:03:23
8,99 ^USD	+22,31%		8,92	-0,78%

29/04	IMMUNITYBIO, INC. : Piper Sandler confirme sa recommandation neutre	ZM
29/04	Les actions de Wallstreetbets sont majoritairement en hausse avant le marché ; Tesla et ImmunityBio progressent.	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Monday; Tesla, ImmunityBio to Advance	29/04
ImmunityBio : Investor Live Audio Webcast – ANKTIVA Post Approval	27/04
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer	26/04
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer	25/04
ImmunityBio, Inc. Announces Positive Overall Survival Results of Anktiva Combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer	25/04
ImmunityBio Announces FDA Approval of ANKTIVA, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	23/04
ImmunityBio Gaining in Tuesday Pre-Market after FDA Approval for Anktiva-Bacterium Combination for Bladder Cancer	23/04
Upcoming Big Tech Earnings Buoy Exchange-Traded Funds, Equity Futures Pre-Bell Tuesday	23/04
Top Premarket Gainers	23/04
ImmunityBio Shares Soar Premarket on FDA Nod for Anktiva	23/04
IN DIRETTA DAI MERCATI: Netweek, Ence Energia, Enel, OVS, Sogefi, Telecom Italia, ASML, Novartis, Airbus, Apple, Nvidia, Boeing...	23/04
EN DIRECTO DESDE LOS MERCADOS: Enagas, Ence Energia, Acerinox, Naturgy, Endesa, Telefónica, Novartis, Apple, Nvidia, Boeing...	23/04
Bolsa de Madrid: Publicación consecutiva de resultados	23/04
US FDA approves ImmunityBio's bladder cancer therapy	23/04
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	23/04
ImmunityBio, Inc. Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	23/04
U.S. FDA approves ImmunityBio's bladder cancer therapy	23/04
ImmunityBio Files Mixed Shelf	17/04
North American Morning Briefing : Markets Steady -2-	26/03
ImmunityBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues ImmunityBio, Inc.

Actions

IBRX

US45256X1037

Autres langues

Filtres